Kronos Worldwide vs LSB Industries
KRO and LXU side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRO and LXU compare
Kronos Worldwide is the larger company, worth 1.2 times as much as LSB Industries ($954M against $823M).
LSB Industries grew revenue faster over the last twelve months (13.0% versus 8.7% for Kronos Worldwide).
LSB Industries keeps more of each dollar of sales as profit, with a net margin of 7.0% compared with −1.9% at Kronos Worldwide.
Kronos Worldwide pays a dividend yielding 2.4%; LSB Industries does not pay one.
LSB Industries scores higher on the StockData Score (11 against 4 for Kronos Worldwide), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRO | LXU |
|---|---|---|
| Size and price | ||
| Market cap | $954M | $823M |
| Share price | $8.29 | $11.43 |
| Change, 1 year | 71.3% | 15.1% |
| Change, 5 years | −40.4% | 17.1% |
| Beta (5Y) | 1.18 | 0.49 |
| Employees | 2,248 | 513 |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/E | – | 18.4× |
| P/S | 0.5× (better) | 1.2× |
| P/B | 1.2× (better) | 1.5× |
| EV/EBITDA | 32.5× | 6.6× (better) |
| P/FCF | – | 12.8× |
| FCF yield | – | 7.8% |
| Fair value | $3.59 | $17.53 |
| Margin of safety | −131% | 34.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.7% | 13.0% (better) |
| Revenue growth, 5Y average | 2.6% | 11.9% (better) |
| Profitability | ||
| Gross margin | 15.3% | 19.9% (better) |
| Operating margin | 2.2% | 11.2% (better) |
| Net margin | −1.9% | 7.0% (better) |
| FCF margin | – | 9.7% |
| Return on equity | −4.7% | 8.7% (better) |
| Return on invested capital | 2.6% | 8.2% (better) |
| Financial health | ||
| Debt / equity | 0.69 (better) | 0.79 |
| Net debt / EBITDA | 11.28 | 1.48 (better) |
| Interest coverage | 0.8× | 2.6× (better) |
| Current ratio | 3.30 (better) | 3.01 |
| Altman Z-score | 2.05 (better) | 2.00 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.4% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −22.6% | – |
| Shareholder yield | 2.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 16.0% | 71.7% |
| Held by insiders | 0.21% | 24.4% |
| Insider net buying, 12 months | $98.5K (better) | −$81.9M |
| Short interest, % of float | 0.94% | 6.8% |
Go deeper
- KRO stock overview
- KRO income statement
- KRO valuation and score
- LXU stock overview
- LXU income statement
- LXU valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.